论文部分内容阅读
目的研究血管紧张素转换酶抑制剂贝那普利对大鼠肝纤维化模型的疗效,以及对其肝组织胰岛素样生长因子-Ⅰ受体(IGF-ⅠR)的影响。方法取Wistar雄性大鼠42只随机分为3组,正常对照组12只,模型组15只,贝那普利治疗组15只。制备四氯化碳诱导的大鼠肝纤维化模型,同时应用贝那普利灌胃,共8周。对肝组织进行苏木精-伊红染色及马松三色染色,观察各组肝纤维化的程度,并测定血清丙氨酸氨基转移酶(ALT)水平,采用SABC免疫组织化学方法检测大鼠肝组织中IGF-ⅠR的表达水平。结果贝那普利治疗组的肝纤维化程度明显较同期模型组轻(P<0.05);与对照组相比,模型组体重降低(P<0.05)及血清ALT升高(P<0.05),IGF-ⅠR在肝组织中表达明显增多(P<0.05),贝那普利治疗组IGF-ⅠR表达减少(P<0.05)。结论贝那普利可改善肝纤维化程度,可能与肝组织IGF-ⅠR的表达减少有关。
Objective To investigate the curative effect of benazepril, an angiotensin converting enzyme inhibitor, on hepatic fibrosis in rats and its effect on insulin-like growth factor-Ⅰ receptor (IGF-ⅠR) in liver. Methods Forty-two Wistar male rats were randomly divided into 3 groups: normal control group (n = 12), model group (n = 15) and benazepril treatment group (n = 15) Preparation of carbon tetrachloride-induced rat liver fibrosis model, while benazepril gavage, a total of 8 weeks. Liver tissues were stained with hematoxylin-eosin and Matson trichrome to observe the degree of hepatic fibrosis in each group. Serum alanine aminotransferase (ALT) levels were measured. SABC immunohistochemistry IGF-IR expression in liver tissue. Results Compared with the control group, the degree of hepatic fibrosis in the benazepril treatment group was significantly lower than that in the control group (P <0.05), and the serum ALT was significantly increased (P <0.05) The expression of IGF-ⅠR in liver tissue was significantly increased (P <0.05), and the expression of IGF-ⅠR in benazepril treatment group decreased (P <0.05). Conclusion Behenopril can improve the degree of liver fibrosis, which may be related to the decrease of IGF-IR expression in liver tissue.